Search Results - "SWILLO, R. E."

Effect of tiplaxtinin (PAI‐039), an orally bioavailable PAI‐1 antagonist, in a rat model of thrombosis by HENNAN, J. K., MORGAN, G. A., SWILLO, R. E., ANTRILLI, T. M., MUGFORD, C., VLASUK, G. P., GARDELL, S. J., CRANDALL, D. L.

“…Objective: To assess the antithrombotic and profibrinolytic effects of tiplaxtinin (PAI‐039), an orally bioavailable antagonist of PAI‐1, in rat models of…”
Get full text

Sphingosine Modulates Myocyte Electrophysiology, Induces Negative Inotropy, and Decreases Survival After Myocardial Ischemia by Friedrichs, Gregory S, Swillo, Robert E, Jow, Brian, Bridal, Terry, Numann, Randy, Warner, Linda M, Killar, Loran M, Sidek, Kurex

“…Contractility studies in isolated feline myocytes have demonstrated that sphingosine, a metabolite stimulated by tumor necrosis factor (TNF) binding, decreases…”
Get full text

Effect of timing of treatment of the glyburide-reversible cardioprotective activity of BMS-180448 by Gomoll, A W, Roth, R A, Swillo, R E, Baird, A J, Sargent, C S, Behling, R W, Malone, H J, Grover, G J

“…The effect of the timing of treatment with the ATP-regulated potassium channel agonist BMS-180448 was evaluated in isolated rat heart and ferret models of…”
Get more information

Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs by Hennan, James K, Swillo, Robert E, Morgan, Gwen A, Keith, Jr, James C, Schaub, Robert G, Smith, Robert P, Feldman, Hal S, Haugan, Ketil, Kantrowitz, Joel, Wang, Phil J, Abu-Qare, Aqel, Butera, John, Larsen, Bjarne D, Crandall, David L

“…The antiarrhythmic and cardioprotective effect of increasing gap junction intercellular communication during ischemia/reperfusion injury has not been studied…”
Get more information

Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis by Hennan, James K, Elokdah, Hassan, Leal, Mauricio, Ji, Allena, Friedrichs, Gregory S, Morgan, Gwen A, Swillo, Robert E, Antrilli, Thomas M, Hreha, Amy, Crandall, David L

“…We tested a novel, orally active inhibitor of plasminogen activator inhibitor-1 (PAI-1) in a canine model of electrolytic injury. Dogs received by oral gavage…”
Get more information

Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis by Hennan, James K, Swillo, Robert E, Morgan, Gwen A, Leik, Courtney E, Brooks, Jonathan M, Shaw, Gray D, Schaub, Robert G, Crandall, David L, Vlasuk, George P

“…Under high shear arterial blood flow von Willebrand Factor (vWF) binds the platelet receptor glycoprotein (GP) Ibalpha, leading to platelet adhesion,…”
Get more information

WAY-140312 reduces plasma PAI-1 while maintaining normal platelet aggregation by Crandall, David L, Hennan, James K, Elokdah, Hassan, Krishnamurthy, Girija, Antrilli, Thomas M, Bauer, Jean S, Morgan, Gwen A, Swillo, Robert E

“…Plasminogen activator inhibitor-1 (PAI-1) is the major physiological inhibitor of tissue plasminogen activator (tPA) and is elevated in diseases of vascular…”
Get full text